Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 4;13(2):503.
doi: 10.3390/nu13020503.

Diagnostic and Pharmacological Potency of Creatine in Post-Viral Fatigue Syndrome

Affiliations
Review

Diagnostic and Pharmacological Potency of Creatine in Post-Viral Fatigue Syndrome

Sergej M Ostojic. Nutrients. .

Abstract

Post-viral fatigue syndrome (PVFS) is a widespread chronic neurological disease with no definite etiological factor(s), no actual diagnostic test, and no approved pharmacological treatment, therapy, or cure. Among other features, PVFS could be accompanied by various irregularities in creatine metabolism, perturbing either tissue levels of creatine in the brain, the rates of phosphocreatine resynthesis in the skeletal muscle, or the concentrations of the enzyme creatine kinase in the blood. Furthermore, supplemental creatine and related guanidino compounds appear to impact both patient- and clinician-reported outcomes in syndromes and maladies with chronic fatigue. This paper critically overviews the most common disturbances in creatine metabolism in various PVFS populations, summarizes human trials on dietary creatine and creatine analogs in the syndrome, and discusses new frontiers and open questions for using creatine in a post-COVID-19 world.

Keywords: GAA; chronic fatigue syndrome; creatine; creatine kinase; post-viral fatigue syndrome.

PubMed Disclaimer

Conflict of interest statement

S.M.O. serves as a member of the Scientific Advisory Board on creatine in health and medicine (AlzChem LLC). S.M.O. owns patent “Sports Supplements Based on Liquid Creatine” at European Patent Office (WO2019150323 A1), and active patent application “Synergistic Creatine” at UK Intellectual Property Office (GB2012773.4). S.M.O. has served as a speaker at Abbott Nutrition, a consultant of Allied Beverages Adriatic and IMLEK, and an advisory board member for the University of Novi Sad School of Medicine, and has received research funding related to creatine from the Serbian Ministry of Education, Science, and Technological Development, Provincial Secretariat for Higher Education and Scientific Research, AlzChem GmbH, KW Pfannenschmidt GmbH, and ThermoLife International LLC. SMO is an employee of the University of Novi Sad. SMO does not own stocks and shares in any organization. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript.

Figures

Figure 1
Figure 1
Possible mechanisms of creatine action in post-viral fatigue syndrome.

Similar articles

Cited by

References

    1. World Health Organization International Classification of Diseases for Mortality and Morbidity Statistics (11th Revision) [(accessed on 15 December 2020)];2019 Available online: https://icd.who.int/browse11/l-m/en.
    1. Unger E.R., Lin J.S., Brimmer D.J., Lapp C.W., Komaroff A.L., Nath A., Laird S., Iskander J. CDC grand rounds: Chronic fatigue syndrome-advancing research and clinical education. MMWR Morb. Mortal. Wkly. Rep. 2016;65:1434–1438. doi: 10.15585/mmwr.mm655051a4. - DOI - PubMed
    1. Lim E.J., Son C.G. Review of case definitions for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) J. Transl. Med. 2020;18:289. doi: 10.1186/s12967-020-02455-0. - DOI - PMC - PubMed
    1. Sandler C.X., Lloyd A.R. Chronic fatigue syndrome: Progress and possibilities. Med. J. Aust. 2020;212:428–433. doi: 10.5694/mja2.50553. - DOI - PubMed
    1. Kim D.Y., Lee J.S., Park S.Y., Kim S.J., Son C.G. Systematic review of randomized controlled trials for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) J. Transl. Med. 2020;18:7. doi: 10.1186/s12967-019-02196-9. - DOI - PMC - PubMed

MeSH terms